Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 27002448)

  • 1. Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.
    Samadder NJ; Neklason DW; Boucher KM; Byrne KR; Kanth P; Samowitz W; Jones D; Tavtigian SV; Done MW; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Davis R; Topham MK; Lynch P; Strait E; McKinnon W; Burt RW; Kuwada SK
    JAMA; 2016 Mar 22-29; 315(12):1266-75. PubMed ID: 27002448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
    Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
    JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
    Samadder NJ; Foster N; McMurray RP; Burke CA; Stoffel E; Kanth P; Das R; Cruz-Correa M; Vilar E; Mankaney G; Buttar N; Thirumurthi S; Turgeon DK; Sossenheimer M; Westover M; Richmond E; Umar A; Della'Zanna G; Rodriguez LM; Szabo E; Zahrieh D; Limburg PJ
    Gut; 2023 Feb; 72(2):256-263. PubMed ID: 35636921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.
    Delker DA; Wood AC; Snow AK; Samadder NJ; Samowitz WS; Affolter KE; Boucher KM; Pappas LM; Stijleman IJ; Kanth P; Byrne KR; Burt RW; Bernard PS; Neklason DW
    Cancer Prev Res (Phila); 2018 Jan; 11(1):4-15. PubMed ID: 29109117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients.
    Sample DC; Samadder NJ; Pappas LM; Boucher KM; Samowitz WS; Berry T; Westover M; Nathan D; Kanth P; Byrne KR; Burt RW; Neklason DW
    BMC Gastroenterol; 2018 Jul; 18(1):115. PubMed ID: 30012100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).
    Ulusan AM; Rajendran P; Dashwood WM; Yavuz OF; Kapoor S; Gustafson TA; Savage MI; Brown PH; Sei S; Mohammed A; Vilar E; Dashwood RH
    Cancer Prev Res (Phila); 2021 Mar; 14(3):325-336. PubMed ID: 33277315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
    van Heumen BW; Roelofs HM; Vink-Börger ME; Dekker E; Mathus-Vliegen EM; Dees J; Koornstra JJ; Langers AM; Nagtegaal ID; Kampman E; Peters WH; Nagengast FM
    Orphanet J Rare Dis; 2013 Aug; 8():118. PubMed ID: 23919274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Metformin in Treatment of Adenomas in Patients with Familial Adenomatous Polyposis.
    Park JJ; Kim BC; Hong SP; Seo Y; Lee HS; Park YS; Na SY; Park SC; Park J; Kim JH; Moon CM; Huh KC; Park SJ; Cheon JH; Kim WH; Kim TI
    Cancer Prev Res (Phila); 2021 May; 14(5):563-572. PubMed ID: 33509804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
    Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
    Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis.
    Nugent KP; Farmer KC; Spigelman AD; Williams CB; Phillips RK
    Br J Surg; 1993 Dec; 80(12):1618-9. PubMed ID: 8298943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulindac for periampullary polyps in FAP patients.
    Richard CS; Berk T; Bapat BV; Haber G; Cohen Z; Gallinger S
    Int J Colorectal Dis; 1997; 12(1):14-8. PubMed ID: 9112144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulindac and Erlotinib for Familial Adenomatous Polyposis.
    Matuchansky C
    JAMA; 2016 Aug; 316(5):544-5. PubMed ID: 27483077
    [No Abstract]   [Full Text] [Related]  

  • 14. Sulindac and Erlotinib for Familial Adenomatous Polyposis--Reply.
    Samadder NJ; Neklason DW; Burt RW
    JAMA; 2016 Aug; 316(5):545. PubMed ID: 27483082
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis.
    Seow-Choen F; Vijayan V; Keng V
    Br J Surg; 1996 Dec; 83(12):1763-6. PubMed ID: 9038563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
    Cruz-Correa M; Hylind LM; Romans KE; Booker SV; Giardiello FM
    Gastroenterology; 2002 Mar; 122(3):641-5. PubMed ID: 11874996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Predicators of Duodenal Familial Adenomatous Polyposis Chemoprevention: Do Chemopreventive Drugs Hit Their Presumed Molecular Targets?
    Shureiqi I
    Cancer Prev Res (Phila); 2018 Jan; 11(1):1-3. PubMed ID: 29263155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, placebo-controlled trial of gastric acid-lowering therapy on duodenal polyposis and relative adduct labeling in familial adenomatous polyposis.
    Wallace MH; Forbes A; Beveridge IG; Spigelman AD; Hewer A; Venitt S; Phillips RK
    Dis Colon Rectum; 2001 Nov; 44(11):1585-9. PubMed ID: 11711728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of chromoendoscopy for surveillance of the duodenum in patients with MUTYH-associated polyposis and familial adenomatous polyposis.
    Hurley JJ; Thomas LE; Walton SJ; Thomas-Gibson S; Haycock A; Suzuki N; Mort M; Williams G; Morgan M; Clark SK; Sampson JR; Dolwani S
    Gastrointest Endosc; 2018 Oct; 88(4):665-673. PubMed ID: 29702101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.